Status:
WITHDRAWN
Magnesium Lactate in the Reduction of Gestational Diabetes Incidence.
Lead Sponsor:
Coordinación de Investigación en Salud, Mexico
Conditions:
Pregnancy Related
Eligibility:
FEMALE
19-35 years
Phase:
NA
Brief Summary
Gestational diabetes, occurs during the second or third trimester of pregnancy, with no prior history of diabetes; this entity can be resolved at the end of pregnancy. Magnesium is the fourth most abu...
Detailed Description
Objective: This study aims to evaluate the efficacy and safety of magnesium lactate oral administration in reducing the gestational diabetes incidence. Design: Randomized, double-blind, placebo-contr...
Eligibility Criteria
Inclusion
- Pregnant women aged 19 to 35 years.
- 12th to 14th gestation weeks.
- Informed consent of the participant.
Exclusion
- Diabetes.
- High blood pressure.
- Hypertriglyceridemia (\>250 g/dL)
- Neoplasia disease.
- Thyroid disease.
- Hepatic disease.
- Consumption of alcoholic beverages.
- Smoking.
- Medication use (thiazide diuretics, anti-blocking agents, calcium antagonists, statins, nicotinic acid, phenytoin, valproic acid, antidepressants, beta-adrenergic, theophylline, glucocorticoids, in the last year)
Key Trial Info
Start Date :
July 31 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04037098
Start Date
July 31 2022
End Date
September 1 2023
Last Update
September 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Biomedical Research Unit. IMSS. Durango
Durango, Durango, Mexico, 34067